Reimagining CLM’s Role in the Biopharmaceutical Space
SirionLabs
JUNE 13, 2022
According to researchers at Tufts University’s Center for the Study of Drug Development, there has been a hefty increase in the total number of procedures across trial phases ; a 69% growth in Phase II and a 49% growth in Phase III. If you’d like to learn more about Sirion CLM, please drop us a line at contact@sirionlabs.com.
Let's personalize your content